

Out. number: 194-00-191/25.09.2026

Publication of materials

for holding an Extraordinary General Meeting of Shareholders of “Sopharma” AD, scheduled for October 30, 2026 and in the absence of a quorum on this date – for November 20, 2026

Sofia, Bulgaria, September 25, 2026 - According to the requirements of Art. 100t of the Law on Public Offering of Securities the Board of directors of **“Sopharma” AD** (SFA: “BSE” AD, SPH: Warsaw Stock Exchange) presents the following materials on the agenda of EGM convened for October 30, 2026 and in the absence of a quorum on this date – for November 20, 2026, to the attention of shareholders, which will be available on the website of Extri News (www.x3news.com), in the FSC system, on the Company's website <https://www.sopharmagroup.com/bg/investitori/korporativni-sabitia/obshto-sabranie-na-aktsionerite> and on the website www.investor.bg, as well as in hard copy at the address of the Company:

1. Minutes of a meeting of the Board of Directors for convening an Annual Meeting of Shareholders of “Sopharma” AD;
2. Invitation to convene the Extraordinary General Meeting of Shareholders (EGM) of “Sopharma” AD;
3. Power of attorney – an example for representing a shareholder at the EGM;
4. Declaration for voting by correspondence – an example for the EGM;
5. **For item 1 of the agenda:** Approval of the 6-month financial report for the first half of 2026– is now available on the website of Extri News (www.x3news.bg), in the FSC system, on the company's website and on the website www.investor.bg;
6. **For item 2 of the agenda:** Approval of a decision under Article 30, paragraphs 5-7 of the Company's Articles of Association for the distribution of profit and payment of an interim dividend based on the adopted 6-month financial report;
7. **For item 3 of the agenda:** Election of a registered auditor to perform a mandatory assurance engagement regarding the sustainability of the consolidated sustainability report of “Sopharma” AD for 2026, if applicable.

Pelagia Viatcheva

Investor Relations Director

Information about the company

"Sopharma" AD

More than 90 years of tradition and modernity - European GMP standards and quality, leader in market cap on the Bulgarian Stock Exchange, good corporate sustainability practices.

The company carries out production and trade of medicinal substances and dosage forms; scientific research and engineering-implementation activities in the field of phytochemistry, chemistry and pharmacy, production of medical devices and cosmetic products, including – plasters, dressing products, medical cosmetics and concentrates for hemodialysis.

Sopharma has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma consistently invests in new technologies, innovations, research and sustainability. The company maintains a dialogue with all interested parties in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated health related business, that operates in important sectors such as medicinal products' manufacturing, hospital supplies, medicinal products' distribution, retail and many others.